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ABSTRACT 
A recent joint meeting was held on January 30, 2014, among the U.S. Food and Drug 
Administration (FDA), National Cancer Institute (NCI), clinical scientists, imaging ex-
perts, pharmaceutical and biotech companies, clinical trials cooperative groups, and pa-
tient advocate groups to discuss imaging endpoints for clinical trials in glioblastoma. This 
workshop developed a set of priorities and action items including the creation of a stand-
ardized MRI protocol for multicenter studies. The current document outlines consensus 
recommendations for a standardized Brain Tumor Imaging Protocol (BTIP), along with 
the scientific and practical justifications for these recommendations, resulting from a se-
ries of discussions between various experts involved in aspects of neuro-oncology neu-
roimaging for clinical trials. The minimum recommended sequences include: 1) parame-
ter matched pre- and post-contrast inversion-recovery (IR)-prepared, isotropic 3D T1-
weighted GRE; 2) axial 2D T2-weighted turbo spin echo acquired after contrast injection 
and before post-contrast 3D T1-weighted images to control timing of images after con-
trast administration; 3) pre-contrast, axial 2D T2-weighted FLAIR; and 4) pre-contrast, 
axial 2D, 3-directional diffusion-weighted images. Recommended ranges of sequence 
parameters are provided for both 1.5T and 3T MR systems. 
 
KEYWORDS 
MRI; Glioblastoma; Clinical Trials; Brain Tumor Imaging Protocol 
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MANUSCRIPT BODY 
Need for Increased Development of Therapeutics for Treating Brain Tumors 
Approximately 67,900 new primary central nervous system (CNS) tumors are diag-
nosed each year in the United States (21 per 100,000 persons) of which 44,910 are ma-
lignant.1 Of these newly diagnosed tumors approximately 28% are gliomas, which consti-
tute 80% of all malignant primary brain tumors.1 Glioblastoma, the most common and 
aggressive type of glioma, is the focus of this document for two reasons. First, it is the 
most common form of high-grade glioma, accounting for 54% of all gliomas and 45% of 
all malignant primary CNS tumors,1 thus it is a high priority area for therapeutic devel-
opment. Second, glioblastoma is one of the most complex and treatment resistant brain 
tumors; therefore, improvements in drug development and measurement of tumor re-
sponse to therapy in glioblastoma may allow advancement of these efforts for other types 
of brain tumors.   
The current standard of care for newly diagnosed glioblastoma patients involves max-
imum safe surgical resection, followed by radiotherapy plus concomitant and adjuvant 
temozolomide,2 but this treatment affords only a median survival of 14 – 16 months, 3-6 
and fewer than 10% of patients survive 5 years beyond diagnosis.7  Furthermore, very 
few therapeutic options exist for recurrent disease since patients with prior temozolomide 
exposure have progression-free survival (PFS) rates at 6 months of 20-40% regardless of 
chemotherapeutic intervention (e.g. nitrosoureas, temozolomide re-challenge, or bevaci-
zumab).5,6,8 Thus, there is an urgent need for drug development in recurrent glioblastoma.  
 
Role of Imaging in Brain Tumor Clinical Trials 
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Although overall survival (OS) is considered the gold standard for determining 
whether a cancer treatment is effective, OS may not directly reflect the specific impact of 
particular treatment regimens because of the confounding effects of known prognostic 
factors (e.g. age, tumor size, neurological status), use of additional therapies prior to or 
after the therapy of interest, and other health-related factors.9,10 Hence, PFS and durable 
objective response rate (ORR) are considered valuable end points for determining the rel-
ative value of a given treatment.11 (Note that PFS also suffers from the impact of prog-
nostic factors). Identifying response and progression has traditionally been based on neu-
roimaging, supported by clinical observation,12 with limited utility of serum or cerebro-
spinal fluid markers of disease for gliomas. However, surrogate measures of tumor bur-
den (e.g., area with contrast uptake), can suffer from issues associated with non-
specificity of the surrogate, measurement variability, false positives, and discordance in 
radiographic interpretation between observers.13 Therefore, response assessment in neu-
ro-oncology needs refinement to minimize intrinsic errors and to improve the accuracy of 
determining true response to a particular therapy.  
A joint meeting was held on January 30, 2014, among the Food and Drug Administra-
tion (FDA), National Cancer Institute (NCI), clinical scientists, imaging experts, clinical 
trials cooperative groups, representatives from pharmaceutical and biotechnology com-
panies, and patient advocate groups to discuss endpoints for clinical trials in glioblasto-
ma.9,10,14,15 With only four drugs for glioblastoma approved by the FDA over the past 30 
years (i.e. nitrosoureas, carmustine, temozolomide, and bevacizumab), significant costs 
associated with large studies, and few survival-extending breakthroughs, there is a need 
to quickly identify effective experimental therapies with a minimum of invested time and 
N-O-D-15-00169R1 
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cost. For example, three large Phase III trials were completed based on promising Phase 
II data, but failed to significantly extend OS.5,6,16 These failures highlight the need to op-
timize the use of imaging as a surrogate tool to better understand the response to novel 
therapeutics. To address these needs, a key recommendation arising from this workshop, 
with the encouragement of the FDA, was the development of a set of priorities and action 
items, including: 1) standardization of the MRI protocol for multicenter studies; 2) vali-
dating the use of volumetric analysis of T1 subtraction maps for defining treatment re-
sponse and failure for use in drug approval studies; and 3) subsequent re-evaluation of the 
current response assessment in neuro-oncology (RANO) criteria with an effort to inte-
grate standardized imaging and quantitative evaluations. These priorities set forth by the 
thought leaders in the neuro-oncology community, the Jumpstarting Brain Tumor Drug 
Development Coalition (consisting of the National Brain Tumor Society (NBTS), Society 
for Neuro-Oncology [SNO], Musella Foundation for Brain Tumor Research, and the Ac-
celerate Brain Cancer Cure [ABC2]), the FDA, and NCI, represent the procedures neces-
sary for validating and building confidence in order to use quantitative imaging surro-
gates as endpoints in glioblastoma clinical trials for drugs.  Indeed, Dr. Richard Pazdur, 
Director   of   the   FDA’s  Office   of  Hematology  Oncology   Products,   shared;;   “During   our  
participation in the Brain Tumor Endpoints Workshop we identified standardization of 
imaging data acquisition and analysis as a step towards increasing the reliability of radio-
graphic endpoints in brain tumor clinical trials, and improving the ability to assess the 
impact of therapies in neuro-oncology.”  
The current document outlines the consensus recommendations for a standardized 
Brain Tumor Imaging Protocol (BTIP), along with the scientific and practical justifica-
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tions for these recommendations, resulting from a series of discussions between various 
experts in neuro-oncology neuroimaging for clinical trials. The recommendations in the 
current document are in direct response to the priorities that resulted from the workshop 
in January 2014, and are supported by the RANO working group.  
 
Need for Imaging Standardization for Better Response Measures 
In multicenter MRI studies, the heterogeneity of MR scanners and parameters (e.g. 
field strength, gradient system, manufacturer, sequences) must be considered. It is well 
known that even minor differences in hardware or sequence timing may result in signifi-
cant changes in image contrast. Lesion contrast is also dependent on the magnetic field 
strength of the scanner,17,18 with higher field strengths showing higher contrast-to-noise 
compared with lower field strength scanners (e.g. 3T vs. 1.5T). Moreover, a variety of 
MR-protocols are commonly used for the same purpose, further hindering interpretation 
of imaging results from different treatment centers in the absence of tight control and 
standardization of image acquisition parameters.  
 
Leveraging  Lessons  from  the  Alzheimer’s  Disease  Neuroimaging  Initiative  (ADNI)  Effort  
to Standardize Structural MRI Acquisition 
Neuroimaging remains at the forefront of medical imaging technology and research; 
however, a lack of benchmarked standard acquisition protocols combined with rapidly 
evolving technologies can limit the ability to combine data in a multicenter fashion. This 
became readily apparent when attempting to study subtle structural changes in the brain 
related   to   degenerative   diseases   such   as  Alzheimer’s   disease.  The   subtle   differences   in  
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acquisition parameters and sequences, along with variations in MR system technologies 
and hardware, resulted in significant measurement discordance across centers, masking 
the effects of the disease. To standardize image acquisition to better understand Alz-
heimer’s   disease,   the   “Alzheimer’s   Disease   Neuroimaging   Initiative”,   or   ADNI   was  
launched in October 2004.19,20 This was a landmark effort to standardize brain imaging 
across clinical centers in the United States and Canada. ADNI was funded as a large pub-
lic-private partnership between the National Institutes of Aging (NIA) and the National 
Institute of Biomedical Imaging and Bioengineering (NIBIB) of the National Institutes of 
Health (NIH), MR system manufacturers, several pharmaceutical companies (Pfizer, Wy-
eth, Eli Lilly, Merck, GlaoSmithKline, AstraZeneca, Novartis, Eisai, Elan, Forest Labora-
tories,  Bristol  Meyers  Squibb)  and  foundations  (Alzheimer’s  Association,  Institute  for  the  
Study of Aging).  
One of the primary, tangible deliverables from ADNI was a standardized anatomic 
MRI protocol for accurate and reproducible brain imaging that is uniform across the ma-
jor MR system manufacturers.21 The ADNI initiative produced a vendor neutral, stand-
ardized, inversion-recovery (IR) prepped volumetric T1-weighted gradient echo sequence 
for quantification of volumetric changes in brain structures, and a dual echo, proton-
density T2-weighted turbo spin echo sequence for quantifying pathologic changes via 
estimates of tissue T2.22 The use of T1-weighted and T2-weighted images are of critical 
importance to brain tumor response assessment, as outlined in the RANO recommenda-
tions and discussed further in the current document. Since the imaging biomarkers and 
MRI pulse sequences of interest in ADNI are very similar to those required for measure-
ment of brain tumor response to therapy, many of the ADNI recommendations were fo-
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cused on the goal of expediting the process of developing a standardized anatomic MRI 
protocol for brain tumors and avoiding many of the pitfalls and expenses encountered by 
ADNI. 
 
Development of MR Image Acquisition Standardization in the European Organization of 
Research and Treatment of Cancer (EORTC) Brain Tumor Group 
The EORTC Brain Tumor Group (BTG) acknowledged the need for standardization 
of MR image acquisition in the context of clinical trials in 2010. A core group of BTG 
members including neuroradiologists, neuro-oncologists and MR physicists, with support 
from EORTC headquarters, developed both a basic and an advanced MR protocol. The 
basic protocol consisted of the core imaging sequences required to assess treatment re-
sponse according to the RANO criteria, i.e. T1- and T2-weighted sequences. The basic 
protocol was deemed mandatory for all participating sites, while the advanced protocol 
was to be adopted by selected sites only. For both protocols, a balance was sought be-
tween feasibility and image quality. Since the protocol was required to be implemented in 
all participating sites throughout Europe, it needed to be feasible both in terms of availa-
ble equipment and scan time. The main issue encountered when trying to implement this 
protocol was that sites were traditionally not selected on the basis of imaging facilities, 
but on their ability to recruit and enroll patients in clinical trials. Radiologists are com-
monly not involved in the impeding EORTC trials, and generally no funding for any ad-
ditional scan time is available in investigator initiated trials. The protocol therefore need-
ed to seamlessly fit into the clinical routine, while ensuring sufficient image quality. The 
development phase was concluded in 2012, after which the protocols were implemented 
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in two newly opened trials: EORTC-26101 and EORTC-26091 (TAVAREC). General 
acceptance of the protocol was high, and only one site indicated that they would be una-
ble to adhere to the protocol. After the initial rollout phase, major protocol violations 
were reduced markedly to below 10%. The excellent adherence indicates that the proto-
col could be implemented into the clinical routine without losing sites for recruitment, 
with a pragmatic but rigorous quality assurance mechanism in place (which is crucial in 
this setting). The BTIP described in the current document has drawn from the EORTC-
BTG experience, and care has been taken to maintain the same level of feasibility. 
 
Philosophical Considerations and Compromises  
During the course of discussions with panel experts, many philosophical concepts and 
approaches were considered resulting in specific notable compromises. The concept of an 
“ideal”  or  “optimized”  protocol  is  elusive  and  ill-defined in terms of the required perfor-
mance measures used for optimization. Instead, a pragmatic approach was considered, 
striving   for  a  balance  between  an  “ideal”  protocol   that  may  be  available  only  on  select  
high-performance systems or at state-of-the-art academic centers, and a protocol that 
could reach large-scale compliance and acceptance from the community, including inter-
national participants. The goal of the initiative was not only to define a protocol for trials 
with reimbursement for imaging by the sponsor but also for use in investigator initiated 
trials without funding or even in daily practice. Thus the suggested protocol needs to ap-
proach what is used in clinical practice in terms of examination time and types of se-
quences.  The concept of tightly controlling acquisition parameters to limit variability 
was felt to be desirable; however, this clearly must be balanced against the practicality of 
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employing such regulations at the large numbers of centers with variable imaging capa-
bilities. With MR systems currently in use at large institutions dating back more than 20 
years, a degree of flexibility was desired in order to allow these centers to still be in-
volved in future clinical trials without significantly affecting image quality or perfor-
mance. In short, perfect can be the enemy of good enough, and what is required here is an 
MRI protocol that is both adequate in terms of quality and feasible at the majority of in-
stitutions. Additionally, we attempted to think progressively and consider aspects related 
to the future of imaging response assessment, namely the potential use of volumetry 
(compared with current bidirectional assessments) for determining response, duration of 
response, as well as the potential for quantifying subclinical measures of tumor response 
including growth kinetics; use of T1 subtraction maps (compared with current evalua-
tions on post-contrast T1-weighted images) to increase lesion conspicuity and more accu-
rately quantify enhancing tumor burden; and the use of dual echo proton-density/T2-
weighted images for estimating tissue T2 (instead of relying solely on T2-“weighted”  im-
ages that are relatively non-specific for delineating nonenhancing tumor from vasogenic 
edema). As many new and promising pulse sequences may be more widely available in 
the future, the panel recommends that the current protocol serve as a well-needed bench-
mark for comparison of future sequences and imaging systems. Any new addition to the 
protocol should be evaluated for its potential to improve treatment evaluation with OS as 
the key endpoint. Lastly, the current recommended protocol was designed to obtain nec-
essary content while minimizing total scan time,  to ideally  30 minutes of actual image 
acquisition, as patient tolerance in this population can be a challenge and patient through-
put is a primary concern for most imaging centers.  
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Recommended MRI Acquisition Protocols 
The recommended minimum requirements for MR image acquisition for use in brain 
tumor clinical trials are outlined in Table 1. This protocol is applicable to both 1.5T and 
3T scanners, although some modifications to scan parameters may be needed to ensure 
similar signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR) in the resulting im-
ages. Additional examples of compliant MR acquisition protocols specific to 3T and 1.5T 
scanners are found in Tables 2 and 3. The total amount of actual scan time (image acqui-
sition only) was benchmarked at approximately 21 minutes and 30 seconds on a 3T Sie-
mens Skyra with parallel imaging, suggesting the entire acquisition including set up and 
tear down can be performed in approximately 30 minutes using current 3T systems. Key 
elements of this protocol include: 1) a pre-contrast, three-dimensional, isotropic, IR-
prepped T1-weighted gradient echo (IR-GRE) sequence; 2) an axial, two-dimensional 
T2-weighted fluid-attenuated inversion recovery (FLAIR) sequence obtained using a tur-
bo-spin echo (TSE) readout; 3) an axial, two-dimensional, three-directional (isotropic) 
diffusion-weighted imaging (DWI) sequence obtained using echoplanar (EPI) or radial 
acquisition; 4) an axial, two-dimensional T2-weighted TSE sequence (dual echo pre-
ferred, but not required); and 5) a post-contrast, three-dimensional, isotropic, T1-
weighted IR-GRE sequence with matching acquisition parameters to pre-contrast T1-
weighted images.  
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Pre- and Post-Contrast Volumetric, IR-Prepared T1-Weighted Gradient Echo MRI  
The use of pre- and post-contrast images (CT or MRI) has been the standard for de-
tection, delineation, and response assessment of malignant brain tumors for more than 60 
years. The most aggressive brain tumors are characterized by angiogenesis and studies 
have demonstrated a clear association between neovascularization and increased malig-
nancy. 23,24 This new vasculature is structurally abnormal, resulting in contrast agent 
leakage from the vascular to the extravascular, extracellular space and increased con-
spicuity of lesions on imaging in the general vicinity of active tumor. T1-weighted MRI 
sequences used after administration of a contrast agent that shortens T1 relaxation time 
are the standard for response assessment due to better soft tissue contrast and lack of ion-
izing radiation with MRI as opposed to contrast-enhanced CT. 
The acquisition of three-dimensional, isotropic T1-weighted images allows for poten-
tial improvements in response assessment, including detection of smaller lesions, use of 
volumetric measurements of enhancing tumor burden and better alignment of tumor re-
gions on subsequent follow up examinations. Data from the literature clearly indicates 
that volumetric measurements of tumor burden and response are equal to or better than 
1D/2D measurements of tumor extent, especially with tumors that are irregular in shape 
such as glioblastoma.  13,25-32 A higher inter-observer variability has been noted when as-
sessments are made using bidirectional or unidirectional measurements compared with 
volumetric quantitation. 33-37 Volumetric changes observed during therapy may be useful 
for quantification of trends in tumor growth or response that provide insight into whether 
a treatment is having an effect on the tumor despite lack of clear radiographic response 
according to the RANO criteria.38 Additionally, a significant limitation of comparisons in 
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tumor size performed on relatively thick (~3-5mm) two-dimensional T1-weighted images 
includes the effects of slightly different slice prescriptions (e.g. different head tilt) on the 
ability to properly align similar slices for side-by-side comparison.39 Acquisition of three-
dimensional isotropic T1-weighted images will provide the ability to easily register or 
align images from subsequent follow-up time points to the baseline scans for more accu-
rate comparisons of tumor size. Also, acquisition of three-dimensional isotropic T1-
weighted images allows for resampling image data along different orientations without 
the need for additional MR acquisitions (e.g. in the sagittal or coronal planes, which are 
often desired for surgical and radiation therapy planning).  
Three dimensional IR-GRE including MPRAGE or IR-SPGR is the most commonly 
used sequence for fast, three dimensional evaluation of tumor burden and has been stud-
ied extensively as a clinical tool in neuro-oncology for nearly twenty years40-44. The use 
of inversion preparation provides superior gray matter-to-white matter image contrast as 
well as significant enhancement of vascular structures; however, there is concern that in-
version preparation may reduce the amount of lesion conspicuity. We considered poten-
tial use of three-dimensional sequences without inversion preparation, but felt the use of 
IR-GRE sequences were warranted given their current widespread use and extensive lit-
erature substantiating their clinical utility. Thus, we recommend three-dimensional iso-
tropic T1-weighted IR-GRE acquisition, available on almost all MR systems as part of 
the standardized ADNI protocol, and in agreement with previous ACRIN, Alliance, and 
EORTC imaging guidelines for brain tumor clinical trials.  
We also considered the potential use of a three-dimensional turbo spin echo (TSE) 
acquisition (e.g. SPACE [Siemens] or CUBE [General Electric]) instead of GRE, which 
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studies have suggested may provide a higher CNR between enhancing tumor and back-
ground tissues. 45 An inherent drawback of the use of three-dimensional GRE acquisition 
is the hyperintensity of blood vessels after contrast agent injection, which may make tu-
mor segmentation more difficult due to increased signal from normal vasculature. The 
use of three-dimensional TSE with the use of a motion-sensitized driven-equilibrium 
preparation has been shown to overcome this limitation by suppressing signal from 
blood. 46 Despite the potential advantages of three-dimensional TSE over GRE, this se-
quence is not available on all MR systems, may require additional costs to purchase these 
sequences, and the specific pulse sequences are not necessarily standardized across ven-
dors. Thus, we recommend three-dimensional isotropic T1-weighted images using a GRE 
acquisition, available on almost all MR systems as part of the standardized ADNI proto-
col, and in agreement with previous ACRIN, Alliance and EORTC imaging guidelines 
for brain tumor clinical trials.  
The use of pre- and post-contrast T1-weighted images with matched sequence param-
eters also allows for use of contrast-enhanced T1-weighted subtraction for tumor visuali-
zation and quantification of enhancing tumor. By subtracting the voxel intensities ob-
tained on pre-contrast T1-weighted images from post-contrast T1-weighted images, con-
trast agent accumulation can be more easily identified and quantified. This technique has 
been used in conjunction with MRI in brain tumors starting in the early 1990s, when Suto 
et al. 47 and Lloyd et al. 48 demonstrated the ability to identify enhancing tumors in the 
presence of blood products. Subsequent studies over the next few decades further estab-
lished the added value of T1-weighted subtraction maps for lesion evaluation during 
standard therapies, and a recent study clearly demonstrated that enhancing tumor could 
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be better identified on T1-weighted subtraction maps during anti-angiogenic therapy,49 
where vascular permeability is markedly reduced. Additionally, T1-weighted subtraction 
maps have been shown to reduce the interobserver variability in lesion volume quantifi-
cation, even in the presence of anti-angiogenic therapies,14 suggesting tumor response 
evaluation may be significantly improved through the use of T1-weighted subtraction 
techniques.  
Ranges of sequence parameters were chosen for volumetric T1-weighted images 
based on known scanner and time limitations. An isotropic resolution of 1mm x 1mm x 
1mm is recommended with full brain coverage (field-of-view of 25.6 cm), but this may 
not be possible with older MR systems or with adequate SNR at 1.5T. Therefore, we rec-
ommend acquiring volumetric T1-weighted images with a maximum resolution of 1.5mm 
x 1.5mm x 1.5mm, particularly for scanners at 1.5T. Additionally, sagittal image acquisi-
tion is recommended over axial acquisition, since sagittal acquisition is faster due to few-
er required slices moving from left-to-right, although post-contrast flow artifacts have 
occasionally been observed. Although standard three-dimensional T1-weighted GRE se-
quences are preferred (e.g. MPRAGE [Siemens & Hitachi] or IR-SPGR [GE]), faster 
volumetric T1-weighted GRE sequences with internal motion compensation may also be 
used under similar acquisition parameters to reduce artifacts (e.g. BRAVO [GE] or VIBE 
[Siemens]). Additional scan parameters and details are documented in Table 1. 
Institutions may desire to collect post-contrast T1-weighted images according to their 
own protocols in addition to the recommended three-dimensional isotropic T1-weighted 
images (e.g. two-dimensional, fat-saturated, T1-weighted TSE images). For compliance 
with the proposed protocol, we recommend additional post-contrast sequences be ac-
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quired after three-dimensional, post-contrast T1-weighted images in order to ensure con-
sistency in terms of the timing of contrast agent injection and acquisition of post-contrast 
T1-weighted images.   
 
Use of Contrast Agents and Consistency of MR Scanners 
Consistency in MR scanning hardware, software, contrast agent dose and contrast 
agent composition is absolutely imperative for maximizing accurate and reproducible se-
rial measurements of tumor size. Patients involved in clinical trials should be scanned on 
the same physical MRI scanner during routine follow-up examinations to the extent this 
is both economically and technically feasible. If this ideal recommendation is not achiev-
able, patients should at the very least be scanned on MRI scanners with the same field 
strength. Although it may be difficult to control the specific contrast agent used for clini-
cal trials, it is critical to use contrast agents with the same chemical composition at each 
follow-up evaluation as baseline to limit potential variability arising from differences in 
contrast agent relaxivity (the amount of MR relaxation effects for a given concentration 
of contrast agent). Additionally, the precise dose and agent should be explicitly docu-
mented on the MR system during acquisition or labeled in the DICOM header (e.g. Con-
trast_BolusAgent (0018,0010) = 1.5cc Gadovist).  
 
Axial, Two-Dimensional, T2-Weighted Turbo Spin Echo (Optional Dual-Echo Proton-
Density/T2-Weighted TSE) MRI 
Damadian50 documented distinct differences in proton relaxation rates between nor-
mal and cancerous tissues as early as 1971, subsequently confirmed by various groups. 51-
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53 Clinical diagnoses and monitoring of the non-enhancing tumor are often performed us-
ing T2-weighted images. Approximately 30-40% of brain tumor patients exhibit non-
enhancing tumor progression prior to changes in contrast enhancement32, and some stud-
ies have described non-enhancing tumor growth and infiltration prior to emergence of 
contrast enhancing progressive disease during anti-angiogenic therapy.54 Further, T2 hy-
perintense lesions are currently used to assess tumor burden in non-enhancing, low-grade 
glioma clinical trials. Therefore, use of T2-weighted images in the proposed protocol is 
recommended for all clinical brain tumor trials.  
The protocol recommended for T2-weighted imaging was based on the parameters 
from ADNI as well as ACRIN, Alliance, and EORTC guidelines in existing trials. The 
recommended slice thickness for 3T scans is 3mm with no interslice gap, and 1.5T scan-
ners should acquire images up to 4mm slice thickness with no interslice gap. (Older 
scanners still in operation may be allowed to acquire data up to a maximum of 5mm slice 
thickness (contiguous) or increase the number of averages with slice thicknesses d4mm 
to ensure comparable SNR to other T2-weighted images acquired with newer systems, 
however, this should be avoided if possible). The recommended echo train length (ETL) 
is between 8 and 16, since an increase in ETL both accelerates acquisition as well as in-
creases inaccuracies55 associated with T2 mapping when using dual echo TSE to estimate 
tissue T2.  
 
Timing of Contrast Agent Injection and Post-Contrast T1-Weighted Images 
A high CNR between tumor and surrounding tissue is criticial for precise measure-
ment of tumor size. In addition to differences in sequences and sequence parameters,56 
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the timing of contrast injection and acquisition of subsequent post-contrast T1-weighted 
images can also lead to variability in tumor size estimation. Dynamic contrast enhanced 
imaging has shown that the maximum contrast agent uptake typically occurs and stabiliz-
es between 4 and 8 minutes after contrast agent application,57 suggesting this may be the 
most effective window for acquiring post-contrast T1-weighted images for minimal vari-
ability in lesion size estimation caused by the timing of contrast agent administration. It is 
important to note that one inherent limitation to implementing a minimal time delay con-
straint is the preferential sensitivity to regions of the tumor with higher vascular permea-
bility and/or blood flow. To standardize the minimal time between contrast agent injec-
tion and acquisition of post-contrast T1-weighted images we recommend acquiring T2-
weighted images after injection and just prior to post-contrast T1-weighted images. Pre-
sumably, T2-weighted images utilizing spin echo or turbo spin echo acquisitions should 
be relatively insensitive to the presence of contrast agent in the vasculature, assuming 
transient changes have already occurred (i.e. assuming it is not during the first pass of the 
bolus injection), such that RANO interpretation and volumetric segmentation of T2-
hyperintense regions should be minimally impacted.  
 
Axial, Two-Dimensional, T2-Weighted Fluid-Attenuated Inversion Recovery (FLAIR) 
MRI 
T2-weighted fluid-attenuated inversion recovery (FLAIR) MRI uses a combination of 
T1- and T2-weighting to suppress the signal originating from bulk fluid including cere-
brospinal fluid. T2-weighted FLAIR techniques increase lesion conspicuity allowing for 
better visualization of vasogenic edema, surgical- and radiation- induced gliosis and infil-
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trating tumor, particularly near the cortex and ventricles where cerebrospinal fluid can 
inhibit lesion detection. Additionally, T2-weighted FLAIR sequences (or T2-weighted 
images) are recommended for determination of non-enhancing tumor progression using 
RANO criteria. 
The preferred protocol for T2-weighted FLAIR imaging was based on guidelines 
from the EORTC, ACRIN, and the Alliance. Similar to T2-weighted MRI, the recom-
mended slice thickness for 3T scans is 3mm with no interslice gap, and 1.5T scanners 
should acquire images up to 4mm slice thickness with no interslice gap. Older scanners 
still in operation may be allowed to acquire data up to a maximum of 5mm slice thickness 
(contiguous) or increase the number of averages with slice thicknesses d4mm to ensure 
comparable SNR to other T2-weighted FLAIR images acquired with newer systems. Also 
note that T2-weighted FLAIR MR images have intrinsically less SNR compared with 
standard T2-weighted MR images. The recommended echo train length (ETL) for T2-
weighted FLAIR images is between 8 and 16.  
Three-dimensional T2-weighted FLAIR techniques are commonly used on newer MR 
systems, but may not be available on all MR systems. A three-dimensional acquisition 
allows for slice reorientation in all three anatomical planes, the potential for quantifica-
tion of T2-hyperintense lesion volumes, and is less sensitive to flow artifacts compared 
with 2D sequences.  Given that three-dimensional acquisition is not universally available, 
the use of this technique, while strongly endorsed, is optional. Protocols or studies con-
sidering the use of 3D FLAIR should use the EORTC recommended parameters listed in 
the footnotes in Table 1.  
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Axial Two-Dimensional Diffusion Weighted Imaging (DWI) 
Diffusion-sensitive MR techniques are routinely acquired as part of standard brain 
MRI protocols, primarily due to the high sensitivity to early ischemic injury as well as 
infection/abscess.  Diffusion-weighted imaging (DWI) is sensitive to microscopic, sub-
voxel water motion, resulting in relatively restricted diffusion in areas of tumor due to 
tightly packed tumor cells. Measures of the apparent diffusion coefficient (ADC) can be 
estimated from the DWI data, reflecting the general magnitude of water motion. In brain 
tumors, ADC has been shown to be a surrogate for cellularity in certain circumstances, 
with ADC inversely correlated with tumor cell density 58-61, suggesting DWI measures of 
ADC may be a useful biomarker for quantifying treatment response.62  
The recommended DWI protocol for routine evaluations is largely based on the 
EORTC, ACRIN, and Alliance recommended protocols as well as the International Soci-
ety for Magnetic Resonance in Medicine (ISMRM) and NCI consensus recommendations 
from 2008.62 Specifically, we recommend three b-values be collected, one at b=0 s/mm2 
(no diffusion weighting), one mid-range b-value of 500 s/mm2, and one higher b-value at 
b=1000 s/mm2. These images should be collected in at least three directions (i.e. x, y, and 
z orientations with respect to the MR system frame of reference). Older MR scanners that 
are not capable of obtaining three or more unique b-values should use b = 0 and b = 1000 
s/mm2. The high b-value for routine DWI in clinical trials should be limited to b=1000 
s/mm2, resulting in a relative signal intensity of 37% of available MR signal if tissue has 
an ADC of 1 um2/ms, commonly associated with mean diffusivity of normal white mat-
ter. The recommended slice thickness for 3T scans is 3mm with no interslice gap, and 
1.5T scanners should acquire images up to 4mm slice thickness with no interslice gap. 
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Older scanners still in operation may be allowed to acquire data up to a maximum of 
5mm slice thickness (contiguous) or increase the number of averages with slice thick-
nesses d4mm to ensure comparable SNR Echo planar imaging (EPI) should be used 
when available. In the event of significant patient motion, a radial acquisition scheme 
may be used (e.g. BLADE [Siemens], PROPELLER [GE], MultiVane [Philips], RADAR 
[Hitachi], or JET [Toshiba]); however, this acquisition scheme can cause significant dif-
ferences in ADC quantification and therefore should be used only if EPI is not an option. 
Additionally, radial acquisition techniques may require considerably more time. 
 
Conclusion 
The proposed recommendations for brain tumor MRI acquisition reflect a balance of 
state-of-the-art imaging technology with techniques that are practically employable 
across the majority of imaging centers involved in multicenter clinical trials. We specifi-
cally recommend this protocol for use in multicenter clinical trials to reduce variability 
associated with response assessment, but also encourage the use of this protocol in rou-
tine clinical practice where it will allow intra-institutional comparisons. The protocol was 
designed to allow flexibility in terms of adding subsequent imaging techniques, such as 
the addition of perfusion MRI prior to acquisition of post-contrast 3D T1-weighted imag-
es, the addition of susceptibility-weighted or gradient echo acquisition before contrast 
injection, or acquisition of post-contrast, 2D T1-weighted TSE images following post-
contrast 3D T1-weighted image acquisition. The current recommendations were designed 
to serve as a benchmark for comparison to future improvements and evaluations.  
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The current recommendations solely involve acquisition of MR images and do not 
provide guidelines for the clinical interpretation or quantitation of tumor extent for the 
purposes of response evaluation. The current protocols were designed to be flexible and 
allow for both current RANO evaluations as well as the potential for future improve-
ments including volumetric analyses.  
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TABLE 1: MINIMUM STANDARD 1.5T & 3T MRI PROTOCOL 
 
 3D T1w Preb Ax 2D 
FLAIRj 
Ax 2D DWI 
Co
nt
ra
st 
In
jec
tio
n a
 
Ax 2D 
T2wh,i 
3D T1w Postb 
Sequence IR-GREe,f TSEc SS-EPIg TSEc IR-GREe,f 
Plane Sagittal/ Axial Axial Axial Axial Sagittal/Axial 
Mode 3D 2D 2D 2D 3D 
TR [ms] 2100m >6000 >5000 >2500 2100m 
TE [ms] Min 100-140 Min 80-120 Min 
TI [ms] 1100n 2000-2500k   1100n 
Flip Angle 10º-15º 90º/t160º 90º/180º 90º/t160º 10º-15º 
Frequency t172 t256 t128 t256 t172 
Phase t172 t256 t128 t256 t172 
NEX t1 t1 t1 t1 t1 
FOV 256mm 240mm 240mm 240mm 256mm 
Slice Thickness d1.5mm d4mml d4mml d4mml d1.5mm 
Gap/Spacing 0 0 0 0 0 
Diffusion Optionsp   b = 0, 500, 
1000 s/mm2 
t3 directions 
  
Parallel Imaging Up to 2x Up to 2x Up to 2x Up to 2x Up to 2x 
Scan Time 
(Approx) 
[Benchmarked on 
3T Skyra] 
5-10 min 
[5:49 for 1mm 
isotropic] 
4-8 min 
[3:22 for 2D 
FLAIR] 
2-4 min 
[1:22 for 3 
direction DWI 
and 3 b-values] 
4-8 min 
[5:10 for 
dual echo] 
5-10 min 
[5:49 for 1mm 
isotropic] 
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a 0.1 mmol/kg dose injection with a Gadolinium chelated contrast agent. Use of a power injector is desirable at an injection rate of 3-5cc/sec.  
b Post-contrast 3D T1-weighted images should be collected with equivalent parameters to pre-contrast 3D T1-weighted images 
c TSE = turbo spin echo (Siemens & Philips) is equivalent to FSE (fast spin echo; GE, Hitachi, Toshiba) 
d FL2D = two-dimensional fast low angle shot (FLASH; Siemens) is equivalent to the spoil gradient recalled echo (SPGR; GE) or T1- fast field echo (FFE; 
Philips), fast field echo (FastFE; Toshiba), or the radiofrequency spoiled steady state acquisition rewound gradient echo (RSSG; Hitachi). A fast gradient echo 
sequence without inversion preparation is desired.  
e IR-GRE = inversion-recovery gradient-recalled echo sequence is equivalent to MPRAGE = magnetization prepared rapid gradient-echo (Siemens & Hitachi) and 
the inversion recovery spoiled gradient-echo (IR-SPGR or Fast SPGR with inversion activated or BRAVO; GE), 3D turbo field echo (TFE; Philips), or 3D fast 
field echo (3D Fast FE; Toshiba). 
f A 3D acquisition without inversion preparation will result in different contrast compared with MPRAGE or another IR-prepped 3D T1-weighted sequences and 
therefore should be avoided. 
g In the event of significant patient motion, a radial acquisition scheme may be used (e.g. BLADE [Siemens], PROPELLER [GE], MultiVane [Philips], RADAR 
[Hitachi], or JET [Toshiba]); however, this acquisition scheme is can cause significant differences in ADC quantification and therefore should be used only if EPI 
is not an option. Further, this type of acquisition takes considerable more time. 
h Dual echo PD/T2 TSE is optional for possible quantification of tissue T2. For this sequence, the PD echo is recommended to have a TE < 25ms.  
i Advanced sequences can be substituted into this time slot, so long as 3D post-contrast T1-weighted images are collected between 4 and 8 min after contrast 
injection.  
j 3D FLAIR is an optional alternative to 2D FLAIR, with sequence parameters as follows per EORTC guidelines: 3D TSE/FSE acquisition; TE=90-140ms; 
TR=6000-10000ms; TI=2000-2500ms (chosen based on vendor recommendations for optimized protocol and field strength); GRAPPAd2; Fat Saturation; Slice 
thickness d 1.5mm; Orientation Sagittal or Axial; FOV d 250 mm x 250 mm; Matrix t 244x244. 
k Choice of TI should be chosen based on the magnetic field strength of the system (e.g. TI | 2000ms for 1.5T and TI | 2500ms for 3T). 
l In order to ensure comparable SNR older 1.5T MR systems can use contiguous (no interslice gap) images with 5mm slice thickness or increase NEX for slice 
thickness d4mm. 
n For Siemens and Hitachi scanners. GE, Philips, and Toshiba scanners should use a TI = 400-450ms for similar contrast.  
m For Siemens and Hitachi scanners. GE, Philips, and Toshiba scanners should use a TR = 5-15ms for similar contrast. 
p Older model MR scanners that are not capable of >2 b-values should use b = 0 and 1000 s/mm2. 
 
Acronyms: 
Ax = Axial; ADC = apparent diffusion coefficient. FLAIR = fluid attenuated inversion recovery; DWI = diffusion-weighted imaging; 3D = three dimensional; TSE 
= turbo spin echo; EPI = echo planar imaging; SS-EPI = single-shot echo planar imaging; GE-EPI = gradient echo echo planar imaging; 2DFL = two-dimensional 
FLASH (fast low angle shot) gradient recalled echo; MPRAGE = magnetization prepared rapid gradient-echo; A/P = anterior to posterior; R/L = right to left; NEX 
= number of excitations or averages; FOV = field of view; TE = echo time; TR = repetition time; TI = inversion time; PD = proton density; DSC = dynamic 
susceptibility contrast; IR-GRE = inversion-recovery gradient-recalled echo 
 
TABLE 2: RECOMMENDED 3T PROTOCOL 
 
 3D T1w Pre Ax 2D FLAIR Ax 2D DWI 
Co
nt
ra
st 
In
jec
tio
n a
 
Ax 2D T2w 3D T1w Postb 
Sequence IR-GREd,e TSEc EPIf TSEc IR-GREd,e 
Plane Sagittal/Axial Axial Axial Axial Axial/Sagittal 
Mode 3D 2D 2D 2D 3D 
TR [ms] 2100g >6000 >5000 >2500 2100g 
TE [ms] Min 100-140 Min 80-120 Min 
TI [ms] 1100h 2500   1100h 
Flip Angle 10º-15º 90º/t160º 90º/180º 90º/t160º 10º-15º 
Frequency 256 t256 128 t256 256 
Phase 256 t256 128 t256 256 
NEX t1 t1 t1 t1 t1 
FOV 256mm 240mm 240mm 240mm 256mm 
Slice Thickness 1mm 3mm 3mm 3mm 1mm 
Gap/Spacing 0 0 0 0 0 
Diffusion Options   b = 0, 500, and 
1000 s/mm2 
t3 directions 
  
Parallel Imaging Up to 2x Up to 2x Up to 2x Up to 2x Up to 2x 
Scan Time 
(Approx) 
5-8 min 4-5 min 3-5 min 3-5 min 5-8 min 
 
a
 0.1 mmol/kg or up to 20cc (single, full dose) of MR contrast. 
b Post-contrast 3D axial T1-weighted images should be collected with identical parameters to pre-contrast 3D axial T1-weighted images 
c TSE = turbo spin echo (Siemens & Philips) is equivalent to FSE (fast spin echo; GE, Hitachi, Toshiba) 
d IR-GRE = inversion-recovery gradient-recalled echo sequence is equivalent to MPRAGE = magnetization prepared rapid gradient-echo (Siemens & Hitachi) and 
the inversion recovery spoiled gradient-echo (IR-SPGR or Fast SPGR with inversion activated or BRAVO; GE), 3D turbo field echo (TFE; Philips), or 3D fast 
field echo (3D Fast FE; Toshiba). 
e A 3D acquisition without inversion preparation will result in different contrast compared with MPRAGE or another IR-prepped 3D T1-weighted sequences and 
therefore should be avoided. 
f In the event of significant patient motion, a radial acquisition scheme may be used (e.g. BLADE [Siemens], PROPELLER [GE], MultiVane [Philips], RADAR 
[Hitachi], or JET [Toshiba]); however, this acquisition scheme is can cause significant differences in ADC quantification and therefore should be used only if EPI 
is not an option. 
g For Siemens and Hitachi scanners. GE, Philips, and Toshiba scanners should use a TR = 5-15ms for similar contrast. 
h For Siemens and Hitachi scanners. GE, Philips, and Toshiba scanners should use a TI = 400-450ms for similar contrast. 
 
Acronyms: 
Ax = Axial; ADC = apparent diffusion coefficient. FLAIR = fluid attenuated inversion recovery; DWI = diffusion-weighted imaging; 3D = three dimensional; TSE 
= turbo spin echo; EPI = echo planar imaging; MPRAGE = magnetization prepared rapid gradient-echo; A/P = anterior to posterior; R/L = right to left; NEX = 
number of excitations or averages; FOV = field of view; IR-GRE = inversion-recovery gradient-recalled echo 
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TABLE 3: RECOMMENDED 1.5T PROTOCOL 
 
 3D T1w Pre Ax 2D FLAIR Ax 2D DWI 
Co
nt
ra
st 
In
jec
tio
n a
 
Ax 2D T2w 3D T1w Postb 
Sequence IR-GREd,e TSEc   EPIf TSEc IR-GREd,e 
Plane Sagittal/Axial Axial Axial Axial Sagittal/Axial 
Mode 3D 2D 2D 2D 3D 
TR [ms] 2100g >6000 >5000 >3500 2100g 
TE [ms] Min 100-140 Min 100-120 Min 
TI [ms] 1100h 2200   1100h 
Flip Angle 10º-15º 90º/t160º 90º/180º 90º/t160º 10º-15º 
Frequency t172 t256 128 t256 t172 
Phase t172 t256 128 t256 t172 
NEX t1 t1 t1 t1 t1 
FOV 256mm 240mm 240mm 240mm 256mm 
Slice Thickness d1.5mm d4mm d4mm d4mm d1.5mm 
Gap/Spacing 0 0 0 0 0 
Diffusion 
Optionsi 
  b = 0, 500, and 
1000 s/mm2 
t3 directions 
  
Parallel Imaging No Up to 2x Up to 2x Up to 2x No 
Scan Time 
(Approx) 
5-10 min 4-5 min 3-5 min 3-5 min 5-10 min 
 
a
 0.1 mmol/kg or up to 20cc (single, full dose) of MR contrast. 
b Post-contrast 2D axial T1-weighted images should be collected with identical parameters to pre-contrast 2D axial T1-weighted images 
c TSE = turbo spin echo (Siemens & Philips) is equivalent to FSE (fast spin echo; GE, Hitachi, Toshiba) 
d IR-GRE = inversion-recovery gradient-recalled echo sequence is equivalent to MPRAGE = magnetization prepared rapid gradient-echo (Siemens & Hitachi) and 
the inversion recovery spoiled gradient-echo (IR-SPGR or Fast SPGR with inversion activated or BRAVO; GE), 3D turbo field echo (TFE; Philips), or 3D fast 
field echo (3D Fast FE; Toshiba). 
e A 3D acquisition without inversion preparation will result in different contrast compared with MPRAGE or another IR-prepped 3D T1-weighted sequences and 
therefore should be avoided. 
f In the event of significant patient motion, a radial acquisition scheme may be used (e.g. BLADE [Siemens], PROPELLER [GE], MultiVane [Philips], RADAR 
[Hitachi], or JET [Toshiba]); however, this acquisition scheme is can cause significant differences in ADC quantification and therefore should be used only if EPI 
is not an option. 
g For Siemens and Hitachi scanners. GE, Philips, and Toshiba scanners should use a TR = 5-15ms for similar contrast. 
h For Siemens and Hitachi scanners. GE, Philips, and Toshiba scanners should use a TI = 400-450ms for similar contrast. 
i Older model MR scanners that are not capable of >2 b-values should use b = 0 and 1000 s/mm2. 
 
Acronyms: 
Ax = Axial; ADC = apparent diffusion coefficient. FLAIR = fluid attenuated inversion recovery; DWI = diffusion-weighted imaging; 3D = three dimensional; TSE 
= turbo spin echo; EPI = echo planar imaging; MPRAGE = magnetization prepared rapid gradient-echo; A/P = anterior to posterior; R/L = right to left; NEX = 
number of excitations or averages; FOV = field of view; IR-GRE = inversion-recovery gradient-recalled echo 
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